Biotech · Public company · Redwood City, CA, US

Jasper Therapeutics, Inc.

Ticker JSPR · SEC CIK 0001788028

Track this companyFree. Adds Jasper Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials50 recruiting or active

Pipeline programs5From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline5

BriquilimabPhase 2 · Chronic Spontaneous UrticariaClinicalTrials.gov · fetched Nov 12, 2026
BriquilimabPhase 2 · Urticaria ChronicClinicalTrials.gov · fetched Nov 12, 2026
Humanized anti-CD117 Monoclonal Antibody (JSP191)Phase 2 · SCIDClinicalTrials.gov · fetched Nov 12, 2026
Humanized anti-CD117 Monoclonal Antibody (JSP191)Phase 1 · MYELODYSPLASTIC SYNDROME; MDSClinicalTrials.gov · fetched Nov 12, 2026
JSP191Phase 1 · Lower-risk Myelodysplastic SyndromeClinicalTrials.gov · fetched Nov 12, 2026

A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria TrialsPHASE2 · TERMINATED · started Nov 26, 2024ClinicalTrials.gov NCT06736262 · fetched Nov 12, 2026
Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU)PHASE1_PHASE2 · COMPLETED · started Nov 29, 2023ClinicalTrials.gov NCT06162728 · fetched Nov 12, 2026
JSP191 (briquilimab) in Subjects with LR-MDSPHASE1 · TERMINATED · started Jun 19, 2023ClinicalTrials.gov NCT05903274 · fetched Nov 12, 2026
JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell TransplantationPHASE1 · COMPLETED · started Jul 8, 2020ClinicalTrials.gov NCT04429191 · fetched Nov 12, 2026
JSP191 Antibody Targeting Conditioning in SCID PatientsPHASE1_PHASE2 · TERMINATED · started Mar 20, 2017ClinicalTrials.gov NCT02963064 · fetched Nov 12, 2026